SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Significant Growth in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 61,800 shares, a growth of 64.4% from the February 13th total of 37,600 shares. Based on an average daily volume of 74,500 shares, the short-interest ratio is presently 0.8 days. Approximately 0.1% of the company’s stock are short sold.

SOPHiA GENETICS Stock Performance

SOPH traded up $0.10 on Friday, hitting $3.22. 30,934 shares of the company’s stock were exchanged, compared to its average volume of 69,767. The company has a current ratio of 3.80, a quick ratio of 3.59 and a debt-to-equity ratio of 0.12. The stock has a fifty day moving average of $3.58 and a two-hundred day moving average of $3.54. SOPHiA GENETICS has a twelve month low of $2.70 and a twelve month high of $6.28. The firm has a market cap of $214.73 million, a PE ratio of -2.95 and a beta of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The business had revenue of $17.73 million for the quarter, compared to the consensus estimate of $17.71 million. On average, research analysts anticipate that SOPHiA GENETICS will post -0.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. lifted its position in SOPHiA GENETICS by 6.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock valued at $5,290,000 after purchasing an additional 86,764 shares during the last quarter. Millennium Management LLC grew its position in SOPHiA GENETICS by 6.5% in the 4th quarter. Millennium Management LLC now owns 698,634 shares of the company’s stock worth $2,180,000 after purchasing an additional 42,689 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of SOPHiA GENETICS by 40.5% in the fourth quarter. Federated Hermes Inc. now owns 100,000 shares of the company’s stock valued at $312,000 after purchasing an additional 28,819 shares during the period. Green Alpha Advisors LLC raised its holdings in shares of SOPHiA GENETICS by 119.3% during the fourth quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock valued at $145,000 after buying an additional 25,686 shares during the last quarter. Finally, Silverberg Bernstein Capital Management LLC acquired a new position in shares of SOPHiA GENETICS during the fourth quarter worth approximately $70,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Analysts Set New Price Targets

SOPH has been the topic of several research reports. BTIG Research set a $5.00 price objective on SOPHiA GENETICS in a research note on Thursday, March 6th. Craig Hallum started coverage on SOPHiA GENETICS in a research report on Wednesday, December 18th. They set a “buy” rating and a $11.00 price target on the stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.